A multicenter, randomized, double-blind, placebo controlled phase III study of monosialoganglioside (GM1) preventing neurotoxicity induced by cisplatin-based chemotherapy in non-small cell lung cancer patients.

被引：0
|
作者：
Zhang, Li
Zhou, Ting
Ma, Yuxiang
Yang, Yunpeng
Fang, Wenfeng
Zhao, Yuangyuan
Hong, Shaodong
Fang, Chan
Zhang, Jiexia
Zhang, Hongyu
Zhao, Hongyun
Huang, Yan
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[3] Hosp Tradit Chinese Med Zhongshan, Zhongshan, Peoples R China
[4] China State Key Lab Resp Dis, Guangzhou, Peoples R China
[5] Guangzhou Inst Resp Dis, Guangzhou, Peoples R China
[6] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China
[8] Sun Yat Sen Univ, Caner Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China
[9] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS10142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS10142
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
    Akiba, Tadashi
    Morikawa, Toshiaki
    Odaka, Makoto
    Nakada, Takeo
    Kamiya, Noriki
    Yamashita, Makoto
    Yabe, Mitsuo
    Inagaki, Takuya
    Asano, Hisatoshi
    Mori, Shohei
    Tsukamoto, Yo
    Urashima, Mitsuyoshi
    CLINICAL CANCER RESEARCH, 2018, 24 (17) : 4089 - 4097
  • [22] Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
    Vansteenkiste, J
    Pirker, R
    Massuti, B
    Barata, F
    Font, A
    Fiegl, M
    Siena, S
    Gateley, J
    Tomita, D
    Colowick, AB
    Musil, J
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (16) : 1211 - 1220
  • [23] A RANDOMIZED, DOUBLE-BLIND PHASE III STUDY OF ICOTINIB VERSUS GEFITINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PREVIOUSLY TREATED WITH CHEMOTHERAPY (ICOGEN)
    Sun, Yan
    Shi, Yankai
    Zhang, Li
    Liu, Xiaoqing
    Zhou, Caicun
    Zhang, Li
    Wang, Dong
    Li, Qiang
    Zhang, Shucai
    Qin, Shukui
    Hu, Chunhong
    Zhang, Yiping
    Tan, Fenlai
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S317 - S318
  • [24] A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN)
    Sun, Y.
    Shi, Y.
    Zhang, L.
    Liu, X.
    Zhou, C.
    Zhang, L.
    Wang, D.
    Li, Q.
    Zhang, S.
    Qin, S.
    Hu, C.
    Zhang, Y.
    Chen, J.
    Song, Y.
    Feng, J. F.
    Cheng, Y.
    Zhang, H.
    Wu, Y. L.
    Xu, N.
    Zhou, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC).
    Tran, HT
    Zinner, R
    Blumenschein, GR
    Oh, YW
    Papadimitrakopoulou, VA
    Kim, ES
    Lu, C
    Malik, M
    Lum, B
    Herbst, RS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 139S - 139S
  • [26] CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).
    Garon, Edward B.
    Ardizzoni, Andrea
    Barlesi, Fabrice
    Cho, Byoung Chul
    De Marchi, Pedro
    Goto, Yasushi
    Kowalski, Dariusz M.
    Lu, Shun
    Paz-Ares, Luis G.
    Spigel, David R.
    Spira, Alexander, I
    Thomas, Michael
    Leung, Mimi
    Baum, Jason
    Zhu, Zewen
    Oliveira Portella, Maria do Socorro
    Yang, James Chih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Weekly Administration of Epoetin Beta for Chemotherapy-induced Anemia in Cancer Patients: Results of a Multicenter, Phase III, Randomized, Double-blind, Placebo-controlled Study
    Tsuboi, Masahiro
    Ezaki, Kohji
    Tobinai, Kensei
    Ohashi, Yasuo
    Saijo, Nagahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (03) : 163 - 168
  • [28] ReTHINK: A randomized, double-blind, placebo controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients.
    Passamonti, Francesco
    Kiladjian, Jean-Jacques
    Vannucchi, Alessandro M.
    Reiter, Andreas
    Bharathy, Savita
    Iommazzo, Dana
    Stalbovskaya, Viktoriya
    Gopalakrishna, Prashanth
    Mesa, Ruben A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial
    Zhang, Zhonghan
    Yang, Yunpeng
    Lu, Ping
    Li, Xiaoqin
    Chang, Jianhua
    Zheng, Rongsheng
    Zhou, Lei
    Chen, Shaoshui
    Chen, Xiaopin
    Ren, Biyong
    Gu, Wei
    Jiang, Xiaodong
    Peng, Jiyong
    Huang, Miaolong
    Feng, Guosheng
    Shen, Peng
    Zhang, Qingyuan
    Zhang, Baihong
    Huang, Yan
    He, Jingdong
    Chen, Yinglan
    Cao, Jingxu
    Wang, Hong
    Li, Wei
    Wan, Huiping
    Nan, Kejun
    Liao, Zijun
    Zhang, Cuiying
    Lin, Zhong
    Zhong, Diansheng
    Xu, Qing
    Liu, Hailong
    Sun, Tao
    Deng, Yanming
    Zhang, Li
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (05)
  • [30] A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer
    Han, Baohui
    Xiu, Qingyu
    Wang, Huimin
    Shen, Jie
    Gu, Aiqin
    Luo, Yi
    Bai, Chunxue
    Guo, Shuliang
    Liu, Wenchao
    Zhuang, Zhixiang
    Zhang, Yang
    Zhao, Yizhuo
    Jiang, Liyan
    Zhou, Jianying
    Jin, Xianqiao
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : 1104 - 1109
12345